Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

MSD’s Bold HIV Drug Combo: Could It Be the Future of Treatment?

Daniel Kim Views  

Medical Today
Medical Today

Merck Sharp & Dohme (MSD) recently reported that a combination of two drugs showed promising results in suppressing HIV-1 replication during two late-stage clinical trials.

MSD seeks new growth drivers to offset the potential hit if its blockbuster cancer immunotherapy Keytruda loses patent protection.

MSD’s clinical trial, involving over 1,000 patients, evaluates the efficacy of combining Doravirine and Islatravir.

One study revealed that MSD’s combination therapy demonstrated a better safety profile compared to Gilead’s HIV drug, Biktarvy. However, in patients already receiving Gilead’s medication, the new treatment didn’t surpass Biktarvy’s effectiveness in suppressing HIV-1, the most prevalent HIV strain.

Meanwhile, MSD intends to submit the clinical trial data to regulatory authorities and present detailed findings at an upcoming conference.

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LIFESTYLE] Latest Stories

  • 3 Worst Foods for Diabetics: Dr. Shin Highlights Key Risks
  • Why Tennis is the Perfect Workout for Your Body and Mind
  • Late-Night Snacking Linked to Higher Blood Sugar and Poorer Heart Health
  • Strength Training Proves Most Effective Treatment for Insomnia in the Elderly
  • Colon Cancer Risk Soars on Low-Carb, Low-Fiber Diet, Says New Research
  • CagriSema Fails to Meet Expectations in Late-Stage Obesity Trial, but Still Beats Placebo
//= do_shortcode('[get-ad-best-list slot_number=2725]'); ?>

You May Also Like

  • 1
    Toyota’s bZ3X SUV Surges with 10,000 Pre-Orders: A New Era in EVs

    BUSINESS 

  • 2
    Telo Trucks' MT1: A 500-HP Compact Pickup That Packs Big Punch in a Small Frame

    BUSINESS 

  • 3
    Xiaomi’s Success vs. Apple’s Failure: What’s the Difference?

    DEBATE 

  • 4
    Mitsubishi Delica D:2 Facelift: New Design, Better Fuel Economy, and Enhanced Safety

    BUSINESS 

  • 5
    Major Vehicle Recall: Over 15,000 Cars Affected Across Multiple Brands in South Korea

    BUSINESS 

Popular Now

  • 1
    Blazer EV SS Hits New Highs: 615 Horsepower and 3.4-Second 0-60 Acceleration

    BUSINESS&nbsp

  • 2
    Trump Defends Tesla, Promises Action Against Violent Attacks

    DEBATE&nbsp

  • 3
    Land Rover’s New Defender 130: Luxury Meets Off-Road Performance in a Seven-Seater

    BUSINESS&nbsp

  • 4
    Honda's New NSX Successor: 1,000 HP Electric Supercar Expected by 2027

    BUSINESS&nbsp

  • 5
    Honda Consolidates Engine Lines in China, Slashing Capacity by 30%

    BUSINESS&nbsp

//= do_shortcode('[get-ad-best-list slot_number=2725]'); ?>

Must-Reads

  • 1
    Toyota’s bZ3X SUV Surges with 10,000 Pre-Orders: A New Era in EVs

    BUSINESS 

  • 2
    Telo Trucks' MT1: A 500-HP Compact Pickup That Packs Big Punch in a Small Frame

    BUSINESS 

  • 3
    Xiaomi’s Success vs. Apple’s Failure: What’s the Difference?

    DEBATE 

  • 4
    Mitsubishi Delica D:2 Facelift: New Design, Better Fuel Economy, and Enhanced Safety

    BUSINESS 

  • 5
    Major Vehicle Recall: Over 15,000 Cars Affected Across Multiple Brands in South Korea

    BUSINESS 

Popular Now

  • 1
    Blazer EV SS Hits New Highs: 615 Horsepower and 3.4-Second 0-60 Acceleration

    BUSINESS 

  • 2
    Trump Defends Tesla, Promises Action Against Violent Attacks

    DEBATE 

  • 3
    Land Rover’s New Defender 130: Luxury Meets Off-Road Performance in a Seven-Seater

    BUSINESS 

  • 4
    Honda's New NSX Successor: 1,000 HP Electric Supercar Expected by 2027

    BUSINESS 

  • 5
    Honda Consolidates Engine Lines in China, Slashing Capacity by 30%

    BUSINESS